AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$PCVX

Wassil Jim sold $1.6M of PCVX

Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.56M total) on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Oct 7, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
medium confidence
Mentioned
$PCVX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership, which can be interpreted as a bearish sign, but the pre‑arranged 10b5‑1 plan may mitigate negative sentiment.

02

Market read

The filing introduces new insider‑sell data that could influence short‑term price action for PCVX.

03

What to watch

Potential upcoming clinical milestones that could offset the sell pressure.

Relevance 5/10Novelty 6/10Timing: after filing today

Background

Form 4 filings provide the first public record of insider transactions, which traders monitor for clues about management's view of the company.

Company-level read

Ticker impact

$PCVXNeutralMedium confidence
Context

EVP Wassil Jim sold 18,000 shares of Vaxcyte for $1.56M via a 10b5‑1 plan, reducing his stake to 145,435 shares.

Expected impact

potential downward pressure as the market prices the insider sell.

Evidence & confidence

The sale is sizable for a mid‑cap biotech and was disclosed via a Form 4, making it a primary source of new information.

Market effects

Sector

May prompt scrutiny of Vaxcyte's pipeline and upcoming data releases.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to the company's shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    Vaxcyte, Inc.

    Biotech firm developing mRNA‑based therapeutics.

  • Individual
    Wassil Jim

    Executive Vice President, Chief Scientific Officer and COO of Vaxcyte.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min